Johnson & Johnson MedTech is celebrating the inaugural National Heart Recovery Awareness Day to raise awareness of heart health and innovative medical technology. The company's Impella platform has been used to treat over 330,000 patients globally, enabling patients to recover their native heart and improve their quality of life.
The Impella ECP pivotal study demonstrated low complication rates and successful closure with a 92% success rate. The 9Fr size of the device provides circulatory support and left ventricular unloading for high-risk PCI procedures.
Results from the DanGer Shock trial show a 12.7% reduction in all-cause mortality with routine use of Impella CP in STEMI and cardiogenic shock patients. The Impella ECP pivotal study will also be presented, demonstrating safety and survival benefits for high-risk PCI patients.
A randomized controlled trial confirms the routine use of Impella CP improves survival in patients who have had a heart attack with STEMI cardiogenic shock. The device reduces 180-day mortality by 12.7% compared to the control arm.
A third-party analysis found that Impella support led to a greater extent of revascularization and lower heart failure and angina symptoms in patients undergoing high-risk percutaneous coronary intervention (PCI). The study showed a 40% greater reduction in residual SYNTAX Score post-PCI with Impella compared to IABP.